Suppr超能文献

过氧化物酶体增殖物激活受体γ(PPARγ)部分激动作用的结构与动力学机制综述

Review of the Structural and Dynamic Mechanisms of PPARγ Partial Agonism.

作者信息

Kroker Alice J, Bruning John B

机构信息

School of Biological Sciences, The University of Adelaide, Adelaide, SA 5005, Australia.

出版信息

PPAR Res. 2015;2015:816856. doi: 10.1155/2015/816856. Epub 2015 Sep 8.

Abstract

PPARγ (peroxisome proliferator activated receptor γ) is a ligand activated transcription factor of the nuclear receptor superfamily that controls the expression of a variety of genes involved in fatty acid metabolism, adipogenesis, and insulin sensitivity. While endogenous ligands of PPARγ include fatty acids and eicosanoids, synthetic full agonists of the receptor, including members of the thiazolidinedione (TZD) class, have been widely prescribed for the treatment of type II diabetes mellitus (T2DM). Unfortunately, the use of full agonists has been hampered by harsh side effects with some removed from the market in many countries. In contrast, partial agonists of PPARγ have been shown to retain favourable insulin sensitizing effects while exhibiting little to no side effects and thus represent a new potential class of therapeutics for the treatment of T2DM. Partial agonists have been found to not only display differences in transcriptional and cellular outcomes, but also act through distinct structural and dynamic mechanisms within the ligand binding cavity compared to full agonists.

摘要

过氧化物酶体增殖物激活受体γ(PPARγ)是核受体超家族的一种配体激活转录因子,它控制着多种参与脂肪酸代谢、脂肪生成和胰岛素敏感性的基因的表达。虽然PPARγ的内源性配体包括脂肪酸和类二十烷酸,但该受体的合成完全激动剂,包括噻唑烷二酮(TZD)类成员,已被广泛用于治疗II型糖尿病(T2DM)。不幸的是,完全激动剂的使用受到了严重副作用的阻碍,许多国家已将其中一些药物撤出市场。相比之下,PPARγ的部分激动剂已被证明在保留良好的胰岛素增敏作用的同时,几乎没有副作用,因此代表了一类治疗T2DM的新的潜在治疗药物。已发现部分激动剂不仅在转录和细胞结果上存在差异,而且与完全激动剂相比,在配体结合腔内通过不同的结构和动力学机制起作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0a6/4578752/a2d3b32e36c9/PPAR2015-816856.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验